Incorporated in 2000, Chimerix is a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir; CMX157, which was licensed to ContraVir pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.
We believe that antivirals that could reduce the frequency of these and other DNA viruses and potentially avoid increasing the risk of other opportunistic infections could provide measurable clinical and pharmacoeconomic benefits for patients and the healthcare system. Through work to date, we see significant opportunities to apply the lipid conjugate technology to other disease categories that are also characterized by a need for effective treatments.
State of Ownership
Business Development Associate Director, University of Michigan
Business Development Executive, Nature Publishing Group, Springer Nature
Sales Account Executive, Springer Nature
Managing Director, Thoroughly Good Consulting